The impact of HLA mismatches on the survival of first cadaveric kidney transplants. 1994

P J Held, and B D Kahan, and L G Hunsicker, and D Liska, and R A Wolfe, and F K Port, and D S Gaylin, and J R Garcia, and L Y Agodoa, and H Krakauer
Department of Internal Medicine, School of Medicine, University of Michigan, Ann Arbor 48103.

BACKGROUND The benefits of HLA-A, B, and DR matching of cadaveric kidney grafts and recipients remain controversial when viewed from the perspective of social equity and graft survival. METHODS We estimated graft survival using proportional-hazards techniques, adjusting for patient and donor characteristics, for a series of 30,564 Medicare patients receiving a first cadaveric kidney transplant between 1984 and 1990. The effects of minimal achievable HLA mismatches and maximal matching on graft survival were estimated by simulated allocation of a sample of organs to a sample of 20,000 candidates for transplantation. RESULTS The adjusted one-year graft survival was 84.3 percent for grafts with no mismatches and 77.0 percent for grafts with four mismatches. National rationing of donor organs to achieve minimal mismatching and maximal matching could potentially decrease the average number of HLA mismatches from 3.6 to 1.2, with a corresponding increase in the number of matches. As a consequence, projected five-year graft survival could potentially increase from 58.5 percent to 62.9 percent. This would be associated with a decrease in the proportion of kidneys allocated to black recipients from 22.2 to 15.0 percent. CONCLUSIONS Under ideal circumstances, a policy of maximal matching of cadaveric renal transplants would increase five-year graft survival by a comparatively small 4.4 percentage points, but the actual benefit is likely to be smaller.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006648 Histocompatibility The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts. HLA Incompatibility,Histoincompatibility,Human Leukocyte Antigen Incompatibility,Immunocompatibility,Tissue Compatibility,Compatibility, Tissue,HLA Incompatibilities,Histocompatibilities,Histoincompatibilities,Immunocompatibilities,Incompatibility, HLA,Tissue Compatibilities
D006680 HLA Antigens Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases. Human Leukocyte Antigen,Human Leukocyte Antigens,Leukocyte Antigens,HL-A Antigens,Antigen, Human Leukocyte,Antigens, HL-A,Antigens, HLA,Antigens, Human Leukocyte,Antigens, Leukocyte,HL A Antigens,Leukocyte Antigen, Human,Leukocyte Antigens, Human
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

P J Held, and B D Kahan, and L G Hunsicker, and D Liska, and R A Wolfe, and F K Port, and D S Gaylin, and J R Garcia, and L Y Agodoa, and H Krakauer
January 1997, Transplantation proceedings,
P J Held, and B D Kahan, and L G Hunsicker, and D Liska, and R A Wolfe, and F K Port, and D S Gaylin, and J R Garcia, and L Y Agodoa, and H Krakauer
April 1988, Gematologiia i transfuziologiia,
P J Held, and B D Kahan, and L G Hunsicker, and D Liska, and R A Wolfe, and F K Port, and D S Gaylin, and J R Garcia, and L Y Agodoa, and H Krakauer
November 1997, Transplantation,
P J Held, and B D Kahan, and L G Hunsicker, and D Liska, and R A Wolfe, and F K Port, and D S Gaylin, and J R Garcia, and L Y Agodoa, and H Krakauer
August 1988, Transplantation proceedings,
P J Held, and B D Kahan, and L G Hunsicker, and D Liska, and R A Wolfe, and F K Port, and D S Gaylin, and J R Garcia, and L Y Agodoa, and H Krakauer
October 1999, Current opinion in immunology,
P J Held, and B D Kahan, and L G Hunsicker, and D Liska, and R A Wolfe, and F K Port, and D S Gaylin, and J R Garcia, and L Y Agodoa, and H Krakauer
May 2008, Transplantation proceedings,
P J Held, and B D Kahan, and L G Hunsicker, and D Liska, and R A Wolfe, and F K Port, and D S Gaylin, and J R Garcia, and L Y Agodoa, and H Krakauer
September 1992, The New England journal of medicine,
P J Held, and B D Kahan, and L G Hunsicker, and D Liska, and R A Wolfe, and F K Port, and D S Gaylin, and J R Garcia, and L Y Agodoa, and H Krakauer
July 1978, Lancet (London, England),
P J Held, and B D Kahan, and L G Hunsicker, and D Liska, and R A Wolfe, and F K Port, and D S Gaylin, and J R Garcia, and L Y Agodoa, and H Krakauer
February 1995, Transplantation proceedings,
P J Held, and B D Kahan, and L G Hunsicker, and D Liska, and R A Wolfe, and F K Port, and D S Gaylin, and J R Garcia, and L Y Agodoa, and H Krakauer
January 1993, The New England journal of medicine,
Copied contents to your clipboard!